Overcoming resistance to EGFR-TKI in NSCLC by simultaneously inhibition of anti-apoptotic proteins

被引：0
作者：
Weller, Sandra
Beigl, Tobias
Essmann, Frank
Harsch, Annika
Kopp, Hans-Georg
Ekstrom, Tom
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6484
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6484
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Triple Trouble: A Case of Multiple Resistance Mechanisms after First Generation EGFR-TKI in NSCLC
    Ralki, Mike
    Maes, Brigitte
    Pat, Karin
    Wynants, Jokke
    Cuppens, Kristof
    CASE REPORTS IN ONCOLOGY, 2019, 12 (02): : 625 - 630
  • [42] Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
    Jiang, Tao
    Li, Aiwu
    Su, Chunxia
    Li, Xuefei
    Zhao, Chao
    Ren, Shengxiang
    Zhou, Caicun
    Zhang, Jun
    ONCOTARGET, 2017, 8 (37) : 62648 - 62657
  • [43] The upregulation of Osteopontin mediates acquired resistance to EGFR-TKI in NSCLC through Integrin/FAK signaling
    Fu, Yulong
    Zhang, Yang
    Liu, Zeyi
    Huang, Jian-An
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [44] EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients with Brain Metastases: A Meta-Analysis
    Xia, X.
    Guo, M.
    He, J.
    Liang, W.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S382 - S382
  • [45] Analysis of Efficacy and Safety of First Generation EGFR-TKI plus Apatinib in Treating Advanced NSCLC after EGFR-TKI Treatment Failure
    Feng, Y.
    Zhu, H.
    Hu, X.
    Liu, Y.
    Xing, P.
    Wang, H.
    Ji, X.
    Dai, Z.
    Shi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S609 - S609
  • [46] Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells
    Yang, Zheng
    Hu, Xiaohui
    Zhang, Shaolin
    Zhang, Wen
    Tam, Kin Yip
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 815 : 80 - 87
  • [47] Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients
    Jiang, Tao
    Ren, Shengxiang
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1235 - S1236
  • [48] EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition
    Nakagawa, Takayuki
    Takeuchi, Shinji
    Yamada, Tadaaki
    Ebi, Hiromichi
    Sano, Takako
    Nanjo, Shigeki
    Ishikawa, Daisuke
    Sato, Mitsuo
    Hasegawa, Yoshinori
    Sekido, Yoshitaka
    Yano, Seiji
    CANCER RESEARCH, 2013, 73 (08) : 2428 - 2434
  • [49] Apatinib combined with EGFR-TKI in treating advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Xu, J.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC
    Hamaguchi, Reo
    Okamoto, Toshihiro
    Sato, Masaaki
    Hasegawa, Michiko
    Wada, Hiromi
    ANTICANCER RESEARCH, 2017, 37 (09) : 5141 - 5145
12345